Japanese emergency use nod for Shionogi's SARS-CoV-2 treatment Xocova

23 November 2022
shionogi-big

Japanese drugmaker Shionogi (TYO: 4507) said yesterday that its Xocova (ensitrelvir fumaric acid, Code No.: S-217622), a novel anti-SARS-CoV-2 drug for COVID-19 obtained emergency regulatory approval from the Ministry of Health, Labor and Welfare (MHLW) in Japan for the indication of SARS-CoV-2 infection, with the news edging the firm’s shares up 2.8% to 7,171 yen.

The company also noted that a contract with the MHLW for the Japanese government to purchase 1 million courses of Xocova is now effective in accordance with the basic agreement for domestic supply of Xocova signed by Shionogi and the MHLW in March 2022.

Shionogi also has a voluntary license agreement for its oral COVID-19 antiviral with the United Nations-backed Medicines Patent Pool (MPP), which aims to increase access to life-saving medicines for low- and middle-income countries (LMICs).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical